Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to comment on Biogaran’s unique strategy of leveraging added solutions, international expansion, and biosimilars. He concludes with his thoughts on the changing dynamics of the pharmaceutical industry and a call for realism regarding the future of the French healthcare system.
I must admittedly say that the generics industry is not being heard as well as we may expect by the [French] government
